NCT01936909View on ClinicalTrials.gov

Interleukin-1 Blockade in Recently Decompensated Heart Failure

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

September 23, 2016

Study Completion Date

September 23, 2016

Conditions
Heart Failure
Interventions
DRUG

Anakinra (weeks 1-2)

Anakinra 100 mg daily for weeks 1 and 2

DRUG

Anakinra (weeks 3-12)

DRUG

Placebo

Trial Locations (1)

23298

Virginia Commonwealth University, Richmond

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Virginia Commonwealth University

OTHER

NCT01936909 - Interleukin-1 Blockade in Recently Decompensated Heart Failure | Biotech Hunter | Biotech Hunter